Robert R. Webb
Arena Pharmaceuticals, Inc.
18 Papers
163 Citations
Robert R. Webb is an academic researcher from Arena Pharmaceuticals, Inc.. The author has contributed to research in topics: Receptor & Chemistry. The author has an hindex of 11, co-authored 18 publications.
Chat about Author
Papers
Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
TL;DR: In vitro data showed that HPMPC has good activity against herpes simplex virus types 1 and 2, although it was 10-fold less potent than acyclovir [AVC, 9-[(2-hydroxyethoxy)methyl]guanine].
148
Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
Brian M. Smith,Jeffrey Smith,James Tsai,Jeffrey A. Schultz,Charles A Gilson,Scott A. Estrada,Rita R. Chen,Douglas M. Park,Emily B. Prieto,Charlemagne S. Gallardo,Dipanjan Sengupta,William Thomsen,Hazel R. Saldana,Kevin Whelan,Frederique Menzaghi,Robert R. Webb,Nigel Robert Arnold Beeley +16 more
TL;DR: Several compounds are shown to be potent and selective 5-HT(2C) receptor agonists, which decrease food intake in a rat feeding model.
118
A new family of H3 receptor antagonists based on the natural product Conessine.
Vincent J. Santora,Jonathan A. Covel,Rena Hayashi,Brian J. Hofilena,Jason B. Ibarra,Michelle D. Pulley,Michael I. Weinhouse,Dipanjan Sengupta,Jonathan Duffield,Graeme Semple,Robert R. Webb,Carleton R. Sage,Albert S. Ren,Guilherme Pereira,Jens Knudsen,Jeff Edwards,Marissa Suarez,John Frazer,William Thomsen,Erin K. Hauser,Kevin Whelan,Andrew J. Grottick +21 more
TL;DR: A new family of Histamine H(3) receptor antagonists (5a-t) has been prepared based on the structure of the natural product Conessine, a known H(2) receptor antagonist, which exhibited promising rat pharmacokinetic properties and demonstrated functional antagonism of the H( 3) receptor in an in-vivo pharmacological model.
36
Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1.
Adrian Folkes,S. David Brown,Lynne Canne,Jocelyn Chan,Erin Engelhardt,Sergey Epshteyn,Richard Faint,Golec Julian M C,Art Hanel,Patrick Kearney,James W. Leahy,Morrison B. Mac,David A. Matthews,Michael P. Prisbylla,Jason Terry Sanderson,Reyna J. Simon,Zerom Tesfai,Nigel Vicker,Shouming Wang,Robert R. Webb,Peter Charlton +20 more
TL;DR: This work has synthesized and evaluated a series of tetramic acid-based and hydroxyquinolinone-based inhibitors of plasminogen activator inhibitor-1 which showed excellent potency against PAI-1.
34
Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine2A Inverse Agonists for the Treatment of Insomnia
Bradley Teegarden,Hongmei Li,Honnappa Jayakumar,Sonja Strah-Pleynet,Peter I. Dosa,Susan D. Selaya,Naomi Kato,Katie Elwell,Jarrod Davidson,Karen Cheng,Hazel R. Saldana,John Frazer,Kevin Whelan,Jonathan Foster,Stephan Espitia,Robert R. Webb,Nigel Robert Arnold Beeley,William Thomsen,Stephen R. Morairty,Thomas S. Kilduff,Hussien A. Al-Shamma +20 more
TL;DR: A series of 5-HT(2A) inverse-agonists that when dosed in rats, both consolidate the stages of NREM sleep, resulting in fewer awakenings, and increase a physiological measure of sleep intensity are described.
30